Chemours Stock Price, News & Analysis (NYSE:CC)

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours declared a quarterly dividend on Wednesday, July 31st. Investors of record on Friday, August 16th will be paid a dividend of $0.25 per share on Monday, September 16th. This represents a $1.00 annualized dividend and a yield of 6.60%. The ex-dividend date is Thursday, August 15th. View Chemours' Dividend History.

Chemours announced that its Board of Directors has approved a stock repurchase plan on Monday, December 4th 2017, which authorizes the company to repurchase $500,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its stock is undervalued.

Chemours Co (NYSE:CC) posted its earnings results on Thursday, August, 1st. The specialty chemicals company reported $0.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.90 by $0.18. The specialty chemicals company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.53 billion. Chemours had a net margin of 10.33% and a return on equity of 71.90%. Chemours's revenue for the quarter was down 22.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.71 EPS. View Chemours' Earnings History.

Chemours is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Chemours.

Chemours will be holding an earnings conference call on Monday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Chemours updated its FY19 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of $2.37-3.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.88.

12 Wall Street analysts have issued twelve-month price targets for Chemours' stock. Their forecasts range from $14.50 to $52.00. On average, they expect Chemours' share price to reach $29.77 in the next year. This suggests a possible upside of 96.5% from the stock's current price. View Analyst Price Targets for Chemours.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chemours.

Media stories about CC stock have trended negative on Friday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chemours earned a news impact score of -2.0 on InfoTrie's scale. They also assigned media coverage about the specialty chemicals company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Chemours.

Chemours saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 12,560,000 shares, an increase of 14.5% from the August 30th total of 10,970,000 shares. Based on an average trading volume of 3,460,000 shares, the short-interest ratio is currently 3.6 days. Approximately 7.8% of the company's shares are short sold. View Chemours' Current Options Chain.

Some companies that are related to Chemours include Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co (GRA), KURARAY CO LTD/ADR (KURRY), Ingevity (NGVT), Univar (UNVR), Balchem (BCPC), Olin (OLN), Innospec (IOSP), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM), Innophos (IPHS) and Hawkins (HWKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include E I Du Pont De Nemours And Co (DD), Micron Technology (MU), NVIDIA (NVDA), DowDuPont (DWDP), Alibaba Group (BABA), AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Pfizer (PFE) and Applied Materials (AMAT).

Chemours' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include DNB Asset Management AS (0.39%), Selz Capital LLC (0.34%), Envestnet Asset Management Inc. (0.10%), NEXT Financial Group Inc (0.06%), AI Financial Services LLC (0.06%) and Brookstone Capital Management (0.05%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, Christian W Siemer, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher. View Institutional Ownership Trends for Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Selz Capital LLC, Zurcher Kantonalbank Zurich Cantonalbank , Nisa Investment Advisors LLC, Brookstone Capital Management, Lau Associates LLC and Envestnet Asset Management Inc.. Company insiders that have sold Chemours company stock in the last year include Amy Trojanowski, Mark Newman and Paul Kirsch. View Insider Buying and Selling for Chemours.

CC stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Pacer Advisors Inc., AI Financial Services LLC, Rothschild Investment Corp IL, State of Alaska Department of Revenue, NEXT Financial Group Inc, Boenning & Scattergood Inc. and Cerebellum GP LLC. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown and Susan M Kelliher. View Insider Buying and Selling for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CC stock can currently be purchased for approximately $15.15.

Chemours has a market capitalization of $2.48 billion and generates $6.64 billion in revenue each year. The specialty chemicals company earns $995 million in net income (profit) each year or $5.67 on an earnings per share basis. Chemours employs 7,000 workers across the globe.View Additional Information About Chemours.

The official website for Chemours is http://www.chemours.com/.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19899. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]